Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.

ABSTRACT:

Background

The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes causing invasive pneumococcal disease (IPD) in China, but will not provide full societal benefits until made broadly available through a national immunization program (NIP).

Objective

To estimate clinical and economic benefits of introducing PCV13 into a NIP in China using local cost estimates and accounting for variability in vaccine uptake and indirect (herd protection) effects.

Methods

We developed a population model to estimate the effect of PCV13 introduction in China. Modeled health states included meningitis, bacteremia

SUBMITTER: Shen K 

PROVIDER: S-EPMC6059448 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature